Regular paperEffects of various dopamine uptake inhibitors on striatal extracellular dopamine levels and behaviours in rats
References (27)
- et al.
Estrous cycle-dependent variation in amphetamine-induced behaviors and striatal dopamine release assessed with microdialysis
Behav. Brain Res.
(1989) - et al.
[3H]GBR-12935: a specific high affinity ligand for labeling the dopamine transport complex
Eur. J. Pharmacol.
(1985) - et al.
High-affinity [3H]GBR 12783 binding to a specific site associated with the neuronal dopamine uptake complex in the central nervous system
Eur. J. Pharmacol.
(1986) - et al.
Methylphenidate-like effects of the new antidepressant drug nomifensine (HOE 984)
Eur. J. Pharmacol.
(1976) - et al.
The substantia nigra and stereotyped behaviour
Eur. J. Pharmacol.
(1972) - et al.
In vivo neurochemical profile of dopamine uptake inhibitors and releasers in rat caudate-putamen
Eur. J. Pharmacol.
(1989) - et al.
Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats
Eur. J. Pharmacol.
(1993) - et al.
Role of calcium ions in dopamine release induced by sodium cyanide perfusion in rat striatum
Neuropharmacology
(1993) Locomotor stereotypy is produced by methylphenidate and amfonelic acid and reduced by haloperidol but not clozapine or thioridazine
Pharmacol. Biochem. Behav.
(1993)- et al.
Calcium receptor antagonists modify cocaine effects in the central nervous system differently
Eur. J. Pharmacol.
(1990)
Evidence for involvement of 5-HT2 and 5-HT1C receptors in the behavioral effects of the 5-HT agonist 1-(2,5-dimethoxy-4-iodophenyl aminopropane)-2 (DOI)
Neurosci. Lett.
The functional significance of neonatal 5,7-dihydroxytryptamine lesions in the rat: response to selective 5-HT1A and 5-HT2,1C agonists
Brain Res. Bull.
The behavioural, but not the hypothermic or corticosterone, response to 8-hydroxy-2-(di-n-propylamino)-tetralin, is antagonized by NAN-190 in the rat
Neuropharmacology
Cited by (64)
Effects of the new psychoactive substances diclofensine, diphenidine, and methoxphenidine on monoaminergic systems
2018, European Journal of PharmacologyCitation Excerpt :In the current study, we present in vitro pharmacological profiles of three NPSs (Fig. 1) that have recently reached the illicit drug market. Diclofensine was originally developed as an antidepressant and was shown to have potent monoamine transporter inhibition potencies in rat brain synaptosomes (Andersen, 1989; Funke et al., 1986; Gasić et al., 1986; Hyttel and Larsen, 1985; Keller et al., 1982) and to increase extracellular dopamine levels in rats (Nakachi et al., 1995). Diphenidine and its methoxylated derivative 2-methoxydiphenidine (methoxphenidine) are NPSs of the diarylethylamine class, which have previously been associated with adverse events including deaths (Elliott et al., 2015; Gerace et al., 2017; Helander et al., 2015; Hofer et al., 2014; Kusano et al., 2017; Lam et al., 2016; Valli et al., 2017).
Mazindol: An alternative in the treatment of awakening disorders and attention deficit?
2012, Medecine du Sommeil